Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
REVB Stock Chart & Stats
$0.90
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.90
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$1.29 - $46.31
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$3.46M
Enterprise Value-$9.95B
Total Cash (Recent Filing)$10.70B
Total Debt (Recent Filing)$746.78M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 08, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding2,623,118
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.87K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-14.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage / Balance-sheet FlexibilityLow debt relative to equity provides durable financial flexibility for a pre-revenue biotech: it reduces near-term insolvency risk, helps preserve capacity to raise incremental capital on acceptable terms, and supports continued R&D funding without immediate pressure from fixed interest obligations.
Near-term Financing Extended RunwayFresh gross proceeds materially extend runway for clinical activities and working capital, reducing near-term funding stress. For a development-stage company, this cash lowers the probability of disruptive emergency financing and allows progression of trials and regulatory interactions over the next several months.
Clinical Program De-risking / Forward PathCompletion of Phase 1b with promising signals and a planned FDA meeting represent meaningful program de-risking. Advancing Gemini toward Phase 2/3 in 2026 increases the potential for durable value creation through clinical milestones, partnerships, or licensing over the medium term.
Bears Say
No Revenue / Persistent LossesZero commercial revenue means reliance on capital markets to sustain operations. Persistent net losses limit earnings visibility and long-term sustainability absent successful clinical outcomes or new funding, forcing continued dilution risk and constraining ability to self-fund development.
High And Worsening Cash BurnSustained negative operating and free cash flow, with a sharp worsening in the latest period, creates structural runway pressure. Over the next 2-6 months this elevates financing frequency, heightens dilution risk, and can force reprioritization or delays of clinical programs if additional capital is unavailable.
Dilution And Financing Execution RiskThe warrant inducement raised cash but created significant dilution and extended exercisability windows. The withdrawal of an expected investor and advisory fees signal challenging financing dynamics, implying ongoing dilution and potentially less favorable terms for future capital raises.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $1.29 and its highest was $46.31 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $3.46M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is May 08, 2026 which is in 66 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Feb 26, 2026. The company reported -$1.65 earnings per share for the quarter, beating the consensus estimate of -$3.66 by $2.01.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Overvalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -1.15.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 2,623,118 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$1.65 in its last earnings report, beating expectations of -$3.66. Following the earnings report the stock price went down -0.752%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
56.11% Insiders
0.17% Mutual Funds
― Other Institutional Investors
43.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---